ZA922239B - Heterocyclic-cyclic amine derivatives. - Google Patents

Heterocyclic-cyclic amine derivatives.

Info

Publication number
ZA922239B
ZA922239B ZA922239A ZA922239A ZA922239B ZA 922239 B ZA922239 B ZA 922239B ZA 922239 A ZA922239 A ZA 922239A ZA 922239 A ZA922239 A ZA 922239A ZA 922239 B ZA922239 B ZA 922239B
Authority
ZA
South Africa
Prior art keywords
heterocyclic
cyclic amine
amine derivatives
compounds
formula
Prior art date
Application number
ZA922239A
Other languages
English (en)
Inventor
Anabella Villalobos
Arthur Adam Nagel
Yuhpyng Liang Chen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA922239B publication Critical patent/ZA922239B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ZA922239A 1991-03-28 1992-03-27 Heterocyclic-cyclic amine derivatives. ZA922239B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67691891A 1991-03-28 1991-03-28

Publications (1)

Publication Number Publication Date
ZA922239B true ZA922239B (en) 1993-09-27

Family

ID=24716559

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA922239A ZA922239B (en) 1991-03-28 1992-03-27 Heterocyclic-cyclic amine derivatives.

Country Status (29)

Country Link
EP (1) EP0646115B1 (fr)
JP (3) JP2659107B2 (fr)
KR (1) KR0179054B1 (fr)
CN (1) CN1044242C (fr)
AT (1) ATE231505T1 (fr)
AU (2) AU658194B2 (fr)
BR (1) BR9205811A (fr)
CA (2) CA2195129C (fr)
CZ (1) CZ289756B6 (fr)
DE (1) DE69232907T2 (fr)
DK (1) DK0646115T3 (fr)
EG (1) EG20281A (fr)
ES (1) ES2188584T3 (fr)
FI (1) FI934223A (fr)
HU (1) HU225047B1 (fr)
IE (1) IE920980A1 (fr)
IL (3) IL116122A0 (fr)
MX (1) MX9201419A (fr)
MY (1) MY108885A (fr)
NO (1) NO304071B1 (fr)
NZ (3) NZ248946A (fr)
PL (3) PL170567B1 (fr)
PT (1) PT100300B (fr)
RU (1) RU2119920C1 (fr)
SG (1) SG49055A1 (fr)
UA (1) UA45944C2 (fr)
WO (1) WO1992017475A1 (fr)
YU (1) YU31392A (fr)
ZA (1) ZA922239B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
CA2116117A1 (fr) * 1991-08-22 1993-03-04 Hiroyuki Sueoka Compose de type benzisoxazole et son utilisation
EP0535496A1 (fr) * 1991-09-25 1993-04-07 Hoechst-Roussel Pharmaceuticals Incorporated (1-Indanon-2-yl)méthylpipéridines, produits intermédiaires et procédé pour leur préparation et leur utilisation comme médicaments
DK0669920T3 (da) * 1992-11-23 2003-05-26 Aventis Pharma Inc Substituerede 3-(aminoalkylamino)-1,2-benzisoxazoler og beslægtede forbindelser
US5494908A (en) * 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
GB9305623D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
DK0788500T3 (da) * 1994-10-26 2004-06-07 Pfizer Fremgangsmåder og mellemprodukter til fremstilling af 5,7-dihydro-3-[2-(1-benzylpiperidin-4-yl)ethyl]-6H-pyrrolo-[4,5-f],2-benzisoxazol-6-on
WO1996025414A1 (fr) * 1995-02-15 1996-08-22 Pharmacia & Upjohn Company Imidazo[1,2-a]pyridines pour le traitement du snc et de cardiopathologies
CN1184478A (zh) * 1995-03-22 1998-06-10 大正制药株式会社 噻唑衍生物
WO1996039397A1 (fr) * 1995-06-06 1996-12-12 Hoechst Marion Roussel, Inc. Derives de benzisoxazole et d'indazole utilises comme agents neuroleptiques
JPH09124643A (ja) * 1995-08-14 1997-05-13 Bristol Myers Squibb Co 抗うつ作用を有する１−アリールアルキル−４−（アルコキシピリジニル）−又は４−（アルコキシピリミジニル）ピペラジン誘導体
US5916902A (en) * 1995-09-13 1999-06-29 Pfizer Inc. Processes and intermediates for preparing 5, 7-dihydro-3- 2-(1-benzylpiperidin-4-yl)ethyl-!6H-pyrrolo- 4, 5-F!-1, 2-benzisoxazol-6-one
US5998415A (en) * 1995-11-02 1999-12-07 Merck Sharp & Dohme Ltd. Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation, and their use of as selective agonists of 5-HT1 -like receptors
FR2751412B3 (fr) * 1996-07-17 1998-09-25 Valbiofrance Methodes de diagnostic in vitro de maladies neurodegeneratives et trousses pour la mise en oeuvre de ces methodes
US6013654A (en) * 1997-08-14 2000-01-11 Pharmacia & Upjohn Company Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases
EP0976404A3 (fr) * 1998-07-30 2001-06-27 Pfizer Products Inc. Compositions pharmaceutiques pour la prévention et la therapie de troubles cognitifes chez les mammifères
HUP0104493A3 (en) 1998-09-30 2002-12-28 Takeda Pharmaceutical Drugs for improving vesical excretory strength
US6951873B1 (en) 1999-04-27 2005-10-04 Pfizer Inc. Methods for treating age-related behavioral disorders in companion animals
EP1050303A3 (fr) * 1999-04-27 2003-01-15 Pfizer Products Inc. Methodes et compositions pour le traitement des troubles du comportement liées à l'age des animaux de compagnie
AU767726B2 (en) * 1999-04-30 2003-11-20 Pfizer Products Inc. Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
PT1209151E (pt) 1999-09-01 2007-05-31 Eisai R&D Man Co Ltd Derivados piperidina 4-substituídos.
EP1300395B1 (fr) 2000-06-21 2009-09-02 Eisai R&D Management Co., Ltd. Compose piperidine 4-substitue
EP1609783A1 (fr) * 2004-06-17 2005-12-28 Neuropharma S.A.U. Composes marines bloquant les canaux calciques pur le traitement de la maladie de alzheimer
DE102005038947A1 (de) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
EP1907384A2 (fr) * 2005-06-30 2008-04-09 Prosidion Limited Agonistes de gpcr
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
US20090318690A1 (en) 2006-04-28 2009-12-24 Eisai R&D Management Co., Ltd. Benzisoxazole Compound
BRPI0812491A2 (pt) * 2007-06-01 2014-12-02 Schering Corp Moduladores de gama secretase
JP5216912B2 (ja) 2008-04-29 2013-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物
JP5411927B2 (ja) 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
AP2739A (en) 2008-09-26 2013-09-30 Boehringer Ingelheim Int Azaindazole compounds as CCRI receptor antagonists
AU2009325902B2 (en) * 2008-12-12 2015-01-29 Idorsia Pharmaceuticals Ltd 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives
KR20120087923A (ko) 2009-10-21 2012-08-07 베링거 인겔하임 인터내셔날 게엠베하 Ｃｃｒ１ 수용체 길항제로서의 인다졸 및 피라졸로피리딘 화합물
WO2011056440A1 (fr) 2009-10-27 2011-05-12 Boehringer Ingelheim International Gmbh Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr1
CN109662964A (zh) 2010-02-09 2019-04-23 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
US8871786B2 (en) 2010-04-30 2014-10-28 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as CCR1 receptor antagonists
WO2012087782A1 (fr) 2010-12-23 2012-06-28 Boehringer Ingelheim International Gmbh Composés de pyrazolopipéridine en tant qu'antagonistes de récepteur ccr1
CA2891122C (fr) 2012-11-14 2021-07-20 The Johns Hopkins University Methodes et compositions pour le traitement de la schizophrenie
CN108658964B (zh) * 2012-11-21 2021-07-02 拉夸里亚创药株式会社 多晶型物
WO2014144663A1 (fr) 2013-03-15 2014-09-18 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
RU2638155C1 (ru) * 2016-02-29 2017-12-12 Общество С Ограниченной Ответственностью "Сай Фарма" Производные бензо[d]изоксазола и их применение
CA3228411A1 (fr) * 2021-08-10 2023-02-16 Xiaomin Zhang Derive de sulfonamide, son procede de preparation et son utilisation medicale

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3488353A (en) 1967-05-29 1970-01-06 Sterling Drug Inc New 1-((2-azaindolyl)-lower-alkyl) 4-substituted-piperazines
JPS51136666A (en) * 1975-05-19 1976-11-26 Dainippon Pharmaceut Co Ltd Process for preparing 3-aminoalkyl-1,2-benzisoxazole derivatives.
US4396770A (en) * 1982-04-09 1983-08-02 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxy-4-phenylpiperidines
IL66866A (en) * 1982-04-09 1987-08-31 Hoechst Roussel Pharma 1-(3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl)-4-(substituted)-piperazines and-piperidines,a process for the preparation thereof,and pharmaceutical compositions containing them
US4489075A (en) * 1982-05-15 1984-12-18 Pfizer Inc. Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants
PH22302A (en) * 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
JPS63234065A (ja) * 1987-03-23 1988-09-29 Mitsubishi Rayon Co Ltd 包接能を有する高分子組成物
JPH0657707B2 (ja) * 1987-05-25 1994-08-03 吉富製薬株式会社 ピペリジン化合物
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4980365A (en) * 1987-07-13 1990-12-25 Hoechst-Roussel Pharmaceuticals Inc. N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
ES2055036T3 (es) * 1988-02-19 1994-08-16 Lilly Co Eli Antagonistas tetrazolicos de receptores de aminoacidos excitadores.
JPH0283375A (ja) * 1988-09-21 1990-03-23 Dainippon Pharmaceut Co Ltd ２−置換ピペラジニル−２−（１，２−ベンズイソキサゾール−３−イル）酢酸誘導体
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
ATE201669T1 (de) * 1991-04-17 2001-06-15 Upjohn Co Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten

Also Published As

Publication number Publication date
NZ248946A (en) 1995-04-27
RU2119920C1 (ru) 1998-10-10
UA45944C2 (uk) 2002-05-15
HUT68357A (en) 1995-06-28
WO1992017475A1 (fr) 1992-10-15
JPH06500794A (ja) 1994-01-27
JP2659107B2 (ja) 1997-09-30
MY108885A (en) 1996-11-30
IL101327A (en) 1998-06-15
CA2195129C (fr) 2002-09-10
IL116122A0 (en) 1996-01-31
EP0646115A1 (fr) 1995-04-05
PL170567B1 (pl) 1997-01-31
ES2188584T3 (es) 2003-07-01
YU31392A (sh) 1994-12-28
FI934223A0 (fi) 1993-09-27
JP3051076B2 (ja) 2000-06-12
JP2000154185A (ja) 2000-06-06
DE69232907T2 (de) 2003-05-15
IL101327A0 (en) 1992-11-15
NO933445L (no) 1993-09-27
NZ242151A (en) 1994-10-26
DE69232907D1 (de) 2003-02-27
CA2107105A1 (fr) 1992-09-29
CN1044242C (zh) 1999-07-21
PT100300B (pt) 1999-09-30
MX9201419A (es) 1992-10-01
JPH10158264A (ja) 1998-06-16
HU225047B1 (en) 2006-05-29
AU1878292A (en) 1992-11-02
PL171914B1 (pl) 1997-06-30
NZ250987A (en) 1997-06-24
CA2195129A1 (fr) 1992-09-29
EP0646115B1 (fr) 2003-01-22
BR9205811A (pt) 1994-06-28
CA2107105C (fr) 2003-10-07
AU658194B2 (en) 1995-04-06
IE920980A1 (en) 1992-10-07
NO933445D0 (no) 1993-09-27
EG20281A (en) 1998-07-30
FI934223A (fi) 1993-09-27
PL171915B1 (pl) 1997-06-30
AU2178895A (en) 1995-09-07
CZ395892A3 (en) 1994-04-13
ATE231505T1 (de) 2003-02-15
KR0179054B1 (en) 1999-03-20
IL116122A (en) 1998-10-30
CZ289756B6 (cs) 2002-04-17
DK0646115T3 (da) 2003-04-22
AU674477B2 (en) 1996-12-19
CN1065267A (zh) 1992-10-14
HU9302733D0 (en) 1993-12-28
NO304071B1 (no) 1998-10-19
SG49055A1 (en) 1998-05-18
PT100300A (pt) 1993-08-31

Similar Documents

Publication Publication Date Title
KR0179054B1 (en) Heterocyclic-cyclic amine derivatives
TWI224595B (en) New benzazepine derivatives, drugs containing these and use of the same for producing drugs
GB9002922D0 (en) 17 beta-substituted-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation
NO944928D0 (no) Fremgangsmåter for inhibering av Alzheimers sykdom
HU9301362D0 (en) Method for producing 4-aryl-piperazines and 4-aryl-piperidines
MY132671A (en) Substituted 6,6-hetero-bicyclic derivatives
FI893433A (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
CA2189007A1 (fr) Methodes pour preparer des formes anhydres et hydratees de derives antihistaminiques de la piperidine; leurs formes polymorphes et pseudomorphes
ATE123024T1 (de) 4-aminopyridinderivate.
GR3022079T3 (en) Preparation of substituted piperidines
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
ATE63309T1 (de) 2,3-dihydro-2-oxo-3-benzofuranylessigs|urederivate und diese enthaltende arzneimittel.
PH24501A (en) Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones
PL346003A1 (en) N-substituted azabicycloheptane derivatives, production and use thereof